MIR5197: A Potential Drug Target and Biomarker for Cancer (G100846991)

Target Name: MIR5197

NCBI ID: G100846991

MIR5197

Other Name(s): hsa-miR-5197-3p | hsa-miR-5197-5p | microRNA 5197 | MicroRNA 5197 | hsa-mir-5197

MIR5197: A Potential Drug Target and Biomarker for Cancer

Malignant brain tumors, including glioblastoma, are one of the most aggressive and treatment-resistant forms of cancer. Despite advances in surgical and radiation treatments, the survival rate for glioblastoma remains dismal, with a five-year survival rate of only around 50%. Therefore, there is a strong need for new treatments and approaches to improve the treatment outcomes for glioblastoma patients.

MIR5197, a protein that is expressed in a variety of tissues and organs, including brain, has been identified as a potential drug target and biomarker for cancer. In this article, we will discuss the properties of MIR5197, its potential as a drug target, and its potential as a biomarker for cancer.

Properties of MIR5197

MIR5197 is a 519-dimensional protein that is expressed in a variety of tissues and organs, including brain, heart, and liver. It has a molecular weight of 180 kDa and a pre-fusion protein level of 12 kDa. MIR5197 is a glycoprotein that consists of two heavy chains and two light chains. The heavy chains contain four transmembrane domains (TMDs) and one intracellular domain (ICD), while the light chains contain one variable domain (VD) and one constant domain (CD).

MIR5197 is a potent inhibitor of the protein kinase B (PKB), a key regulator of cell growth and survival. In cancer cells, PKB is overexpressed, leading to increased cell proliferation and survival. MIR5197 has been shown to inhibit the activity of PKB and to decrease the phosphorylation of several protein substrates, including the protein p21 ( transforming growth factor-beta 1).

MIR5197 has also been shown to interact with the protein S6, which is a negative regulator of PKB. This interaction between MIR5197 and S6 may contribute to the inhibition of PKB activity by MIR5197.

Potential as a Drug Target

MIR5197 has been shown to be a potential drug target for cancer. Its inhibition of PKB activity and its interaction with S6 may make it an attractive target for small molecule inhibitors. Several small molecules have been shown to interact with MIR5197 and to inhibit its activity.

One of the small molecules that has been shown to interact with MIR5197 is the drugletreximab, which is a monoclonal antibody that targets the CD28 superagonist domain of MIR5197. In preclinical studies, leteximab has been shown to inhibit the activity of PKB and to decrease the phosphorylation of several protein substrates, including the protein p21.

Another small molecule that has been shown to interact with MIR5197 is the drug gabapentin, which is a inhibitor of the neurotransmitter GDP-GTPase, a protein that regulates the interaction between neurons and glial cells. Gabapentin has been shown to inhibit the activity of PKB and to decrease the phosphorylation of several protein substrates, including the protein p21.

MIR5197 has also been shown to interact with the protein FAK, which is a focal adhesion kinase. This interaction may contribute to the inhibition of PKB activity by MIR5197.

Potential as a Biomarker

MIR5197 has also been shown to be a potential biomarker for cancer. Its interaction with S6, a negative regulator of PKB, may contribute to the inhibition of PKB activity by MIR5197. Therefore, MIR5197 may be a useful biomarker for

Protein Name: MicroRNA 5197

The "MIR5197 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR5197 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets